Free Trial

C4 Therapeutics (CCCC) Competitors

C4 Therapeutics logo
$1.52 +0.01 (+0.66%)
Closing price 04:00 PM Eastern
Extended Trading
$1.52 0.00 (0.00%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CCCC vs. RAPP, ERAS, BNTC, ITOS, RVNC, ABVX, FULC, SLDB, CKPT, and TECX

Should you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Rapport Therapeutics (RAPP), Erasca (ERAS), Benitec Biopharma (BNTC), iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), Abivax (ABVX), Fulcrum Therapeutics (FULC), Solid Biosciences (SLDB), Checkpoint Therapeutics (CKPT), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry.

C4 Therapeutics vs. Its Competitors

Rapport Therapeutics (NASDAQ:RAPP) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

78.8% of C4 Therapeutics shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Rapport Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 1 mentions for Rapport Therapeutics and 0 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.89 beat Rapport Therapeutics' score of 0.93 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Rapport Therapeutics Positive
C4 Therapeutics Very Positive

Rapport Therapeutics has higher earnings, but lower revenue than C4 Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rapport TherapeuticsN/AN/A-$78.31M-$3.45-3.42
C4 Therapeutics$35.58M3.03-$105.32M-$1.47-1.03

Rapport Therapeutics presently has a consensus price target of $28.00, suggesting a potential upside of 137.29%. C4 Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 689.47%. Given C4 Therapeutics' higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Rapport Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapport Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
C4 Therapeutics
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Rapport Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -259.60%. Rapport Therapeutics' return on equity of -25.48% beat C4 Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rapport TherapeuticsN/A -25.48% -24.63%
C4 Therapeutics -259.60%-45.86%-28.96%

Summary

C4 Therapeutics beats Rapport Therapeutics on 8 of the 14 factors compared between the two stocks.

Get C4 Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CCCC vs. The Competition

MetricC4 TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$107.22M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-1.0321.3126.1719.90
Price / Sales3.03278.47414.67113.66
Price / CashN/A41.4736.1356.90
Price / Book0.507.518.055.38
Net Income-$105.32M-$55.05M$3.15B$248.50M
7 Day Performance-1.30%2.45%1.85%2.97%
1 Month Performance14.29%7.33%4.81%6.02%
1 Year Performance-66.37%5.38%34.86%20.39%

C4 Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CCCC
C4 Therapeutics
2.0124 of 5 stars
$1.52
+0.7%
$12.00
+689.5%
-68.9%$107.22M$35.58M-1.03150
RAPP
Rapport Therapeutics
1.9166 of 5 stars
$10.88
-0.4%
$32.67
+200.2%
N/A$398.55MN/A0.00N/ANews Coverage
ERAS
Erasca
3.0715 of 5 stars
$1.39
+1.5%
$4.57
+228.9%
-44.3%$388.10MN/A0.00120Positive News
BNTC
Benitec Biopharma
1.6325 of 5 stars
$14.57
-0.3%
$23.83
+63.6%
+66.7%$383.52M$80K-9.6520High Trading Volume
ITOS
iTeos Therapeutics
3.2341 of 5 stars
$10.11
+1.5%
$15.86
+56.8%
-33.4%$381.21M$35M-3.3390
RVNC
Revance Therapeutics
2.7157 of 5 stars
$3.65
flat
$8.45
+131.5%
N/A$381.02M$234.04M-1.89500
ABVX
Abivax
2.4554 of 5 stars
$6.11
+2.3%
$31.00
+407.4%
-43.5%$378.82MN/A0.0061Positive News
FULC
Fulcrum Therapeutics
0.3287 of 5 stars
$7.17
+2.6%
$6.29
-12.3%
+8.4%$377.58M$80M-102.41100
SLDB
Solid Biosciences
3.4191 of 5 stars
$4.51
-5.8%
$14.90
+230.4%
-26.6%$371.30M$8.09M-1.51100
CKPT
Checkpoint Therapeutics
0.5593 of 5 stars
$4.26
flat
$4.33
+1.7%
N/A$370.71M$41K-2.3210News Coverage
TECX
Tectonic Therapeutic
3.4747 of 5 stars
$18.75
-5.4%
$82.33
+339.1%
+26.8%$369.90MN/A0.00120

Related Companies and Tools


This page (NASDAQ:CCCC) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners